John Bishay, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by Merck at 45.4% of the total. 2025 is the largest year on record at $65,731, more than ten times the $3,394 reported in 2019. Among urology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 495 payments — averaging $278.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$63K
- Johnson & Johnson$23K
- Intuitive Surgical$13K
- Janssen Scientific Affairs, LLC$11K
- AstraZeneca$6K
- Astellas Pharma US Inc$4K
- plus $18K from 43 others
Across 291 payments — averaging $11,721 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$3.4M
What the payments were for
- Consulting fees$35,66726%
- Speaking & faculty fees$65,70548%
- Travel & lodging$10,5018%
- Food & beverage$17,28813%
- Education$8,5846%
- Gifts$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$60,769
- Da Vinci Surgical System$12,539
- RYBREVANT$9,048
- CARVYKTI$9,048
- Erleada$5,976
- PADCEV$3,000
- ADSTILADRIN$2,557
- UroLift$2,026
- Nubeqa$900
- Xofigo$872
- AquaBeam Robotic System$762
- SpaceOAR VUE System - 10mL$600
- JELMYTO$583
- Axonics r-SNM System$543
- UroLift System$512
- ORGOVYX$336
- PROVENGE$331
- Axonics$305
- Bulkamid$258
- AMS$235
How this compares
$137,786 in reported general payments places this provider in the 95th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 57 | $774,959 |
| XtandiEnzalutamide | 66 | $765,804 |
| NubeqaDarolutamide | 33 | $388,318 |
| Abiraterone Acetate | 211 | $252,184 |
| OrgovyxRelugolix | 58 | $154,021 |
| MyrbetriqMirabegron | 167 | $99,380 |
| GemtesaVibegron | 53 | $28,341 |
| Tamsulosin Hcl | 698 | $11,198 |
| Potassium Citrate ErPotassium Citrate | 39 | $4,501 |
| Testosterone | 20 | $2,767 |
| Finasteride | 334 | $2,720 |
| Methenamine Hippurate | 30 | $2,658 |
| Oxybutynin Chloride ErOxybutynin Chloride | 167 | $2,502 |
| Solifenacin Succinate | 52 | $1,574 |
| Prednisone | 198 | $1,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $3,963 | $865,184233 claims |
| Johnson & JohnsonErleada | $23,150 | $774,95957 claims |
| BayerNubeqa | $2,069 | $388,31833 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $11,179 | $252,184211 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $430 | $182,362111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 urology providers in Nebraska.
Other urology in Omaha
- Rebecca McCreryOmaha$71K
- Judson DaviesOmaha$67K
- Stefanie BolteOmaha$59K
- Michael FeloneyOmaha$29K
- Andrew TrainerOmaha$12K
- Stephen LeslieOmaha$12K
- Jon MortonOmaha$11K
- Brett HillOmaha$11K
- John HorganOmaha$10K
- Larry SirefOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.